Activating this element will cause content on the page to be updated.
Mounjaro In Dubai, Abu Dhabi And Al Ain
Tirzepatide, the active component in Mounjaro In Dubai, was employed in the Phase 3 SURMOUNT-1 weight loss clinical trials that lasted for 72 weeks. Average weight loss after using tripeptide ranged from 15% at the 5mg dose to 19.5% at the 10mg dose, 20.9% at the 15mg dose, and 3.1% with the placebo. Patients with diabetes were not eligible to participate in the experiment.